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Background: Qualitative alterations or abnormal expression of microRNAs (miRNAs) in colon cancer have mainly
been demonstrated in primary tumors. Poorly overlapping sets of oncomiRs, tumor suppressor miRNAs and
metastamiRs have been linked with distinct stages in the progression of colorectal cancer. To identify changes in
both miRNA and gene expression levels among normal colon mucosa, primary tumor and liver metastasis samples,
and to classify miRNAs into functional networks, in this work miRNA and gene expression profiles in 158 samples
from 46 patients were analysed.
Results: Most changes in miRNA and gene expression levels had already manifested in the primary tumors while
these levels were almost stably maintained in the subsequent primary tumor-to-metastasis transition. In addition,
comparing normal tissue, tumor and metastasis, we did not observe general impairment or any rise in miRNA
biogenesis. While only few mRNAs were found to be differentially expressed between primary colorectal carcinoma
and liver metastases, miRNA expression profiles can classify primary tumors and metastases well, including
differential expression of miR-10b, miR-210 and miR-708. Of 82 miRNAs that were modulated during tumor
progression, 22 were involved in EMT. qRT-PCR confirmed the down-regulation of miR-150 and miR-10b in both
primary tumor and metastasis compared to normal mucosa and of miR-146a in metastases compared to primary
tumor. The upregulation of miR-201 in metastasis compared both with normal and primary tumour was also
confirmed. A preliminary survival analysis considering differentially expressed miRNAs suggested a possible link
between miR-10b expression in metastasis and patient survival. By integrating miRNA and target gene expression
data, we identified a combination of interconnected miRNAs, which are organized into sub-networks, including
several regulatory relationships with differentially expressed genes. Key regulatory interactions were validated
experimentally. Specific mixed circuits involving miRNAs and transcription factors were identified and deserve
further investigation. The suppressor activity of miR-182 on ENTPD5 gene was identified for the first time and
confirmed in an independent set of samples.
Conclusions: Using a large dataset of CRC miRNA and gene expression profiles, we describe the interplay of
miRNA groups in regulating gene expression, which in turn affects modulated pathways that are important for
tumor development.
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Table 1 Patient data
Characteristics
No of patients (n) 46
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The dysregulation of microRNA (miRNA) expression in
tumors compared with normal counterparts has been
observed in many hematologic and solid tumors. Several
miRNAs have been proposed to act as tumor-suppressor or
tumor-promoting genes [1], and specific miRNA expression
signatures with potential prognostic significance have
been observed in various primary tumors analysed so
far, including colon, lung, pancreatic cancer and neuro-
blastoma. Interestingly, pre-malignant lesions (such as
adenomas) share identical alterations in miRNA expression
with carcinoma, suggesting that the acquisition of cancer-
specific profiles represents an early event in the malignant
process [2].
The role of miRNAs in metastasis development is less
clearly defined, and contradictory results in this field
have been reported, depending on the experimental system
studied, the cellular and tissue context, and the step of
the metastatic process analysed. A number of so-called
oncomiRs have been identified for their ability to influence
key steps in the metastatic process directly [3-5]. In some
cases, sets of metastasis-associated miRNAs different
from those involved in tumorigenesis have been reported
[6]. For instance, specific miRNAs are involved in circuits
regulating the epithelial to mesenchymal transition (EMT),
a critical step which drives tumor metastasis [7]. The
major limitation of these studies is that functional data
have mainly been collected by means of in vitro assays
with tumor cell lines, and only a limited number of
studies have been carried out in vivo.
Colorectal cancer (CRC) is a leading cause of cancer-
related mortality in the USA and Europe [8,9]. Improved
treatment strategies involving surgery, chemo- and radio-
therapy have increased the overall survival rates in early
stages, but tumor recurrence (particularly in lymph-node-
positive cancers) is frequent. About one-third of CRC pa-
tients develop synchronous or metachronous metastases in
the liver. The 5-year overall survival rate of patients with
CRC decreases from 80-90% in the case of locally confined
tumors, to 40-60% in locally advanced non-metastatic
tumors, and to only 5-10% in metastatic tumors [10].
Over the last few years, various miRNA expression patterns
observed in primary colorectal tumors have been associated
with tumor stage and patient survival [11-13], while
only few miRNAs are common to all reported expression
profiles. An interesting example is miR-21, high levels of
which in CRC compared with normal colon tissue have
been associated with poor prognosis and unfavorable
therapeutic response, independently of well-established
clinical predictors [14,15]. In the same studies, other
differentially expressed miRNAs, i.e., miR-20a, miR-106a,
miR-181b, miR-203 and miR-143, were analysed for their
prognostic value, but the strength of their association with
poor survival was less robust. Although clinical andpathological parameters are available for the prognostic
stratification of CRC patients, more comprehensive know-
ledge of the basic features of colorectal tumorigenesis and
metastatic process may have important implications for
both scientific and clinical research and could help in
answering a variety of long- standing questions. For
instance, the frequency of epigenetic and transcriptional
changes occurring in primary versus metastatic lesions is
still an open issue.
In this study, we performed a genome-wide expression
analysis of both miRNA and genes in primary tumors,
liver metastases and normal colon mucosa from CRC
patients, with the aim of discovering modulated miRNAs
and genes in tumor and metastasis development and
to identify the regulatory networks involved in tumor
progression.
Results
Matched miRNA and gene expression in normal colon
mucosa, primary colon carcinoma and liver metastasis
We determined the miRNA expression profiles of 78
samples (23 normal colon mucosa, N; 31 primary colon
carcinoma, T; and 24 liver metastases, M), obtained
from 46 patients (Table 1). This dataset included 24
samples belonging to 8 patients with matched samples
(N, T and M) from the same patient. To understand
how changes in miRNA expression can influence gene
expression, we also examined the expression profiles of
22,517 genes in 80 samples, including 23 N, 30 T and
27 M, and comprising 27 matched samples from 9
patients (Table 2). Data are available at the GEO database
(GSE35834).
Of 847 miRNAs represented in the array, 309 were con-
sidered for later analyses after filtering (see Methods). Simi-
larly, 30% of genes with low expression profile variability
Table 2 Sample set description for miRNA and gene
array datasets

































For both miRNA and gene array samples, column 3 shows number of patients
for whom paired data for various tissue type combinations were available; last
column reports total number of samples for each tissue type.
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highly variable expression profiles were considered further.
Unsupervised hierarchical cluster analysis was performed
on selected miRNAs and genes. Normal samples clustered
together and were relatively well separated from T and M
samples, both according to unsupervised hierarchical
cluster analysis based on miRNA and on gene expression
data (Figure 1A). In fact, only miRNA expression profiles
separated T from M quite well. Considerable per-patient
pairing of T and M samples was observed in both dendro-
grams, in which triplets and pairs of samples from the same
patient are shown in the same color (see also Additional
file 1: Figure S1). In roughly 25% of patients, the M samples
were more similar to the T from which they had derived,
rather than to the M samples of other patients. The similar-
ity between T and M samples of the same patient was more
evident when samples were classified according to gene
expression (20% and 28% of per-patient sample pairing, in
miRNA- and gene-based heatmaps, respectively).
miRNA expression variability in the two main transitions
in the N-T-M progression was evaluated, by considering
the number of miRNAs and genes resulting up- or down
modulated (absolute fold-change > 1) or unchanged in the
T vs N and in the M vs T comparisons. Figure 1B shows
that most expression variation took place in the T vs N
comparison, revealing two alternative patterns of miRNA(and gene) expression variation in the progression: i)
miRNAs (genes) up- or down-modulated in the compari-
son T vs N and basically stable in M vs T (Figure 1B, left),
and ii) miRNAs (genes) unchanged in T vs N and modu-
lated in M vs T (Figure 1B, right).Differentially expressed miRNAs
Many significantly differentially expressed miRNAs
(DEMs) can be found during tumor progression. The
whole set of samples with miRNA expression data was
considered in unpaired tests (e.g., all T vs all N samples).
Other sample subsets matched by patient were consid-
ered for paired comparisons (Additional file 1: Methods
and Results and Additional file 1: Figure S2).
By considering the larger unpaired dataset, we identi-
fied 62, 63 and 11 DEMs in T vs N, M vs N and M vs T
comparisons, respectively (Additional file 1: Table S1).
Several miRNAs were significantly modulated in more
than one contrast. Only 5 miRNAs varied merely when
M and T samples were compared (miR-146a, miR-15a,
miR-15b, miR-196a, miR-708). Of 53 DEMs shared by at
least two comparisons, 25 were always under- and 26
over-expressed, whereas two miRNAs did not follow the
same trend in the various comparisons. miR-100 and
mir-99a, both putative tumor suppressors, were under-
expressed in T vs N and over-expressed in M vs T.
Identification of DEM confirmed that more miRNAs
are modulated in T vs N than in M vs T comparison;
however, DEMs in metastasis compared with primary
tumors may be of great importance, since they include
miR-10b, miR-210 and miR-708, which are key regulators
of several processes related to disease progression, such
as DNA repair, angiogenesis, hypoxia, EMT induction,
and cancer recognition by the immune system [16-18].
Additional file 1: Figure S3 shows the expression profiles
of 22 miRNAs involved in EMT which were differentially
expressed in T vs N and/or M vs T comparisons.miRNA biogenesis is not impaired during cancer
progression
According to our results, during tumor progression we
could not detect either general impairment of miRNA
biogenesis or an overall increase in miRNA expression. In
fact, in both T vs N and/or M vs T contrasts, we observed
a comparable number of up- and down-modulated DEMs:
29 and 33 were respectively up- and down-modulated in
T vs N; as against 5 and 6 in M vs T. Regarding global
miRNA expression, when we considered the distribution
of all DEM expression levels measured in N, T and M,
again we could not find any significant differences between
the groups (mean values 6.10, 5.95 and 6.01, respectively;
p-value of pairwise mean equality t-test >0.7).
Figure 1 miRNAs and gene expression in normal colon mucosa, primary tumor and liver metastases. (A) Sample classification based on
309 miRNAs and 15,761 gene expression profiles. Color-coding of samples reported in different lines refers to tissue type (Normal colon mucosa,
N; primary colorectal cancer, T and liver metastasis, M) and per-patient matching of samples. (B) miRNA and gene expression variability in two
main tumor progression transitions. (C) Venn diagram of intersections among DEMs identified by unpaired test applied to different comparisons.
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To assess the reproducibility of the identified miRNAs, we
used qRT-PCR to measure the expression of 5 miRNAs,
both in the same 78 samples used for miRNA expression
profiling and in an independent set of 21 samples obtained
from matched samples of 7 patients. We quantified three
down-regulated (miR-150, miR-10b, miR-146a) and two
up-regulated miRNA (miR-210 and miR-122). miR-150 was
the most down-regulated miRNA in the T vs N compari-
son; miR-10b was significantly down-regulated in all three
contrasts; miR-122 and miR-146a were differentially
expressed in the M vs T comparison; and miR-210 was up-
regulated in the M vs T and M vs N comparisons. For each
of the above miRNAs, the Spearman rank correlation test
between qRT-PCR expression estimation ( 2ΔCt ) and
array-based expression level, in the same 78 samples, was
significant (p < 0.01) (Additional file 1: Figure S4A). miR-
150 and miR-146a were also tested on an independent set
of 21 samples (N, T and M samples from 7 new patients)
and the results were fully consistent with microarray-based
observations, confirming miR-150 down-regulation in T
vs N and miR-146a down-regulation in M vs T (Additional
file 1: Figure S4B).
The expression level of miR-122, a miRNA which is highly
expressed in the liver, was significantly higher in M than in
T, suggesting the residual presence of normal liver tissue in
metastasis samples. miR-122 expression was evaluated in
samples in which normal colon mucosa and liver tissue had
been mixed in different proportions. qRT- PCR analysis
showed that mixing up to 95% of N with 5% of liver tissuecaused a significant increase in miR-122 expression, com-
pared with samples with 100% of N tissue. This result indi-
cates that the presence of only 5% of liver cells in a sample
significantly increases miR-122 expression.
Identification of most probable miRNA targets and
definition of regulatory networks modulated in
development of tumor and metastasis
We obtained a set of 77 samples (23 N, 29 T, 25 M) with
matched miRNAs and gene expression data from the
same biological sample. The combined analysis of target
prediction and expression of 305 miRNAs with predicted
targets and 12,748 target genes allowed us to reconstruct
post-transcriptional regulatory networks describing the
most probable regulatory interactions and circuits active
in transitions characterizing tumor development and
progression.
miRNAs interact in several ways with target mRNAs,
and may exert non-canonical regulatory actions, but
they commonly act post-transcriptionally by altering the
stability of target mRNAs. The expression profile of a
given miRNA was therefore expected to be inversely
correlated with that of its target genes. To identify the
most probable miRNA targets, we first adopted a classical
approach, to enrich a large set of predicted miRNA targets
in truly regulated genes, by identifying significant negative
correlations between miRNAs and predicted target
expression profiles [19,20]. With the selected threshold on
correlation significance (see Methods), we identified 3,078
relations, involving 117 miRNAs and 1,423 target genes
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than 1 out of 1,500 miRNA/target relations predicted by
miRSVR turned out to be supported by expression data.
Indeed, among supported relationships, 2,690 (87%) were
based on predicted target sites, which are conserved across
species, whereas only one-quarter of the original predic-
tions involved conserved sites (see Methods).
The number of supported target genes per miRNA
ranged from 1 to 216, with an average value of 26.3.
About half the genes were supported targets of only one
specific miRNA, whereas other genes were putatively
regulated by up to 10 different miRNAs.
Within the whole group of supported target genes, of
particular importance are the various subsets of genes
significantly differentially expressed (DEGs), which may be
viewed as the prominent effects of post-transcriptional
regulatory action exerted by miRNAs.
As previously stated, in the unpaired analysis only 5
miRNAs appeared to be significantly modulated in the
transition from primary tumor to metastasis, whereas the
number of DEMs observed in the comparison between
normal tissue and primary tumor and metastasis was
higher (Figure 1C). It is reasonable to assume that DEMs,
being moderately to highly expressed in all the considered
samples and those most variable in each contrast, are
responsible for most target repression. Thus, for the T vs
N and M vs N comparisons, we focused only on DEMs
up- and down-regulated in each contrast with a fold
change (FC) > 3 and with an average expression over
background in at least one of the two contrasted
groups. The intersection between the post- transcriptional
network and the results of miRNA differential expression
analysis induced various sub-networks, describing post-
transcriptional regulatory circuits involving those miRNAs
whose expression variation may be important for tumor
development and progression. Figures 2A and 3A show
post-transcriptional regulatory networks with miRNAs
differentially expressed in the T vs N comparison and
their supported relations with target genes. Two network
components are observed, involving respectively 6 up-
regulated (Figure 2A) and 17 down-regulated (Figure 3A)
DEMs. The component regarding the 6 up-regulated
miRNAs was smaller, and a large fraction of genes
appeared to be regulated by miR-182. The largest compo-
nent involved 17 down-regulated DEMs, which putatively
regulated a number of targets about twice as high as that
observed for the whole set of miRNAs. A large proportion
of the predicted target genes were indeed significantly
differentially expressed. This was more evident for the
up-regulated miRNA component, in which 62 down- reg-
ulated DEGs accounted for 27% of the supported targets
of up-regulated DEMs. Conversely, our analysis predicted
that only a few genes would be targets of more than one
up-regulated miRNA. Among the interactions predictedbetween miRNA and target genes identified in the T vs N
regulatory network we considered the relationship between
miR-145 and c-Myc. qRT-PCR analysis of the entire set of
samples confirmed the opposite behavior of miR-145 and
c-Myc in tumour progression (Figure 3B).
The network involving five DEMs observed in the M vs
T comparison and their supported target genes was small
and consisted of five unconnected components (Additional
file 1: Figure S5). No DEGs were observed among the
supported targets of DEMs in the T to M transition. These
results further support the concept that the main change
in the transcriptome occurs early in the CRC progression.
miR-10b expression in metastases: potential association
with survival
The 26 miRNAs included in the TN and MT networks
(Additional file 1: Table S3) were considered for survival
analysis. The expression of miR-10b measured in liver
metastasis showed a statistically significant association
with the survival of patients affected with stage IV CRC
(hazard ratio = 1.47, 95% confidence interval = 1.23-1.75;
adjusted p-value: 0.00052). The effect of miR-10b on
prognosis is given in Additional file 1: Figure S6, which
shows that patients with high levels of miR-10b expression
in their metastatic disease have a shorter time to event
(median survival: 8 months) compared with those with
low levels (51 months). In our study, the expression levels
of miR-10b measured in primary tumors had no signifi-
cant impact on prognosis.
miR-182 controls ENTPD5
miR-182 was one of the most upregulated DEMs in the
T vs N contrast. Among its predicted target genes we
focused on ENTPD5, due to the involvement of the gene
product in energy metabolism. Since ENTPD5 resulted
significantly down-regulated in our analysis, and another
study provided support for downregulation during cancer
progression [21], we decided to study the relationship
between miR-182 and its predicted target gene ENTPD5.
To investigate the opposite behavior of the miRNA and its
target gene, we performed qRT-PCR to measure miR-182
and ENTPD5 expression in a panel of five cell lines
(CG-705, HT29, from a primary colorectal tumor, and
MICOL-S, MICOL-14, and LoVo, from colorectal car-
cinoma metastases [22]). As shown in Figure 2B, all
tumor cell lines showed an inverse correlation (−0.85,
p-value < 0.05) between high expression of miR-182 and
low expression of ENTPD5. This result not only confirms
the microarray profiling data but also suggests a role of
the anti-correlated relationship in conferring some advan-
tageous properties to the tumor cells. We next wanted to
provide support to the direct targeting of ENTPD5 by miR-
182. To this end, we performed a Luciferase reporter assay
in HEK293T cells transfected with a construct containing
Figure 2 Post-transcriptional regulatory network of miRNAs up-modulated in T (primary tumor) vs N (normal colon mucosa) contrast.
(A) The bipartite network represents DEMs up-modulated (FC > 3) in T vs N comparison (red triangles), supported target genes (circles) and their
relations (gray dotted lines). Target DEGs in T vs N contrast are shown in blue, other genes in grey. The pink solid line outlines the experimentally
validated miR-182/ENTPD5 relation. (B) Inverse correlation between miR-182 and ENTPD5 expression, according to qRT-PCR in 5 colon cancer cell
lines and a pool of normal tissue. (C) Luciferase reporter assay of 3′UTR region of ENTPD5 and miR-182. Average relative light units (RLU) of
biological replicates compared with control (HEK293T pMIR-ENTPD5), non-target RNA (HEK293T pMIR-ENTPD5 non-target RNA) and miR-182
over-expression (HEK293T pMIR-ENTPD5 miR-182). Data shown as means ± standard deviation (SD) of mean of three experiments performed in
triplicate. * P < 0.05 vs N or control. **P < 0.01 vs N or control. nRQ: normalized Relative Quantity.
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(pMIR-ENTPD5). When cells were co-transfected with
miR-182, a 50% reduction in luciferase expression was
observed, compared with cells transfected with negative
control RNA or pMIR-ENTPD5 only (Figure 2C).miRNA modulated KEGG pathways
For the T vs N contrast, we identified pathways enriched
in gene targets of DEMs, the expression of which changes
in the comparisons, and in DEG targets of DEMs, with
only partially overlapping results. Some pathways, such
as “Cell cycle”, “Purine metabolism” and “Pathways in
cancer”, were found in both cases, whereas others,
such as “P53 signaling” was identified by the first, less
conservative strategy. Conversely, “Wnt signaling” and
“Colorectal cancer” pathways were found to be specif-
ically enriched in DEG targets of DEMs (Additional file 1:
Table S4). It should be noted that “Pathways in cancer”
is a collection of many pathways, including various cancer
hallmarks such as EMT, and is an indication that manyimportant processes may be under the control of identi-
fied miRNAs.
Mixed regulatory circuits involving interplay of miRNAs
and transcription factors contain many “cancer genes”
miRNAs regulate target genes mainly at the post-transcrip-
tional level, operating in highly interconnected regulatory
networks and pathways, with complex cross-talk of miRNAs
and transcription factors (TFs), which are frequently mas-
ter regulators of biological processes. miRNA expression
can be activated or repressed by transcription factors
(TFs), whereas mRNAs encoding TFs can be silenced by
miRNAs. In many cases, key mixed regulatory circuits
involve miRNAs, TFs and common target genes. Thus,
miRNAs and TFs can form feedback or feedforward loops,
cooperating to switch or tune gene expression.
To account for the interplay of miRNAs and TFs,
we have recently developed a new method for the inte-
grated analysis of target prediction, MAGIA2 [23], which
allows one to dissect regulatory complexity by exploiting
target predictions, in combination with information on
Figure 3 Post-transcriptional regulatory network of miRNAs down-modulated in T vs N contrast. (A) The bipartite network represents
DEMs down-modulated (FC > 3) in T vs N comparison (green triangles), supported target genes (circles) and their relations (gray dotted lines).
Target DEGs in T vs N contrast are shown in orange, other genes in grey. The pink solid line outlines an experimentally validated relation.
(B) Inverse correlation between c-Myc and miR-145 expression according to quantitative qRT-PCR in 78 samples of N, T and M samples used for
gene profiling. Quantification normalized to expression of DACT1 and miR-200c, respectively. Data shown as means ± standard deviation (SD) of
mean of three experiments performed in triplicate. **P < 0.01 vs N. nRQ: normalized Relative Quantity.
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tions, and which can identify both negative and positive
expression profile correlations. By applying this method to
the matched expression profiles of all genes and to the 70
DEMs in TN and/or MT comparisons, we were able to
reconstruct mixed regulatory networks involving miRNAsand TFs. Our results show that 18 miRNAs are involved
in the strongest 127 interactions identified as significant by
MAGIA2 (Additional file 1: Figure S7A). Then, we focused
on the identification of two types of triangular mixed
circuits representing putative feed-forward or feed-back
loops with interplay between transcriptional and post-
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regulates both a given miRNA and its target gene, and
(ii) circuits in which one miRNA regulates both a given
TF and its regulated gene. Additional file 1: Figure S7B
reports 20 significant mixed circuits involving five distinct
miRNAs which interact with 6 TFs and 15 non-TF
protein-coding genes.
Discussion
A straightforward interpretation of the data published
thus far is complicated by the relatively small overlap
between results obtained with differing analytical platforms,
sample cohorts and bioinformatics methods [24]. In this
study, we carried out a genome-wide integrative analysis
of miRNA and gene expression profiles in 77 CRC
samples, including normal colon mucosa, primary tumor
and liver metastasis, in order to identify miRNA-gene
relationships significantly supported by expression data
and involving differentially expressed miRNAs, with the
ultimate aim of discovering regulatory circuits and miRNA-
affected cellular pathways specifically associated with tumor
progression.
As shown in breast cancer by Farazi et al. [25], we
observed that both miRNA and gene expression profiles
efficiently separate tumor from normal samples. However,
miRNAs proved to be more informative than genes in
distinguishing primary colorectal tumors from liver
metastases. Interestingly, gene expression profiles from
tumor and metastatic samples obtained from the same
patient tended to cluster together. Thus, based on its gene
expression profile, a liver metastasis is more similar to the
matched primary tumor than to the liver metastases of
other patients, suggesting that metastasis development is
a patient-specific process.
The large majority of miRNAs and genes with varied
expression in the T vs N comparison remain stable after
metastasis development (59 miRNAs out of 62, 95%; 424
genes out of 455, 93%). Three-quarters of miRNAs
modulated in the M vs T comparison are invariant in
the T vs N comparison (9 out of 12), whereas only 50%
of genes are modulated in the M vs T comparison but not
in the previous one.
DEMs between sample classes were identified, consid-
ering the whole set of samples and the smaller group of
per-patient matched samples in parallel. The six- fold
lower number of DEMs observed in the M vs T contrast,
compared with T vs N (and M vs N) contrasts, indirectly
indicates the similarity between tumor and metastatic
tissues. This is particularly remarkable also considering
that, as discussed for miR-122, a normal liver contribution
to M transcriptome cannot be completely ruled out.
It has been hypothesized that miRNA down-regulation
fosters invasive and metastatic behavior of cancer cells,
since overall reduction of miRNA expression levels hasbeen reported as a general trait of human cancers [26],
and repression of miRNA biogenesis in cancer cell lines
promotes cell proliferation and invasion [27]. In contrast,
Volinia et al. [28] showed that the most common event in
solid tumors is gain in miRNA expression, whereas Farazi
et al. [25], comparing normal and cancer tissues, did not
detect any change in total miRNA content. We did not
observe any prevalence of up- or down-regulation of
miRNAs in our tumor samples, either when considering
the numbers of up- and down-regulated miRNAs (29 and
33, respectively, in the T vs N contrast) or when comparing
the distributions of absolute expression values of DEMs in
the same contrast.
miRNAs differentially expressed between tumor and
normal mucosa include ones previously described as
members of a “signature” common to various types of
solid tumors [1]. Many of them have also been implicated
in the molecular and biological processes which drive
tumorigenesis in CRC (Additional file 1: Tables S1 and
S2). Relevant examples are miR-143, miR-145, miR-125b
and miR-21 (associated with cell growth and survival), the
miR-17-92 cluster, miR-20 and miR-100 (involved in
uncontrolled cellular proliferation), the miR-183 cluster
and miR-31 (implicated in cell migration), and miR-150
(potential biomarker of prognosis and therapeutic out-
come in CRC). Interestingly, miR-139-5p, the most down-
regulated in the T vs N comparison, has very recently been
identified as a member of a signature predictive of the
clinical aggressiveness of stage II CRC [29]; in addition,
miR-224, the most up-regulated together with miR-183 in
the same comparison, has been identified for its ability
to distinguish CRC by means of proficient or deficient
DNA mismatch repair machinery [30]. For some of these
miRNAs, the tumor-promoting or -suppressing functions
in both CRC and other tumors have already been sug-
gested. However, considering the large number of mRNAs
regulated by each miRNA, it is very likely that two or
more genes from different molecular pathways may be
altered in their expression and, considering the tissue
specificity of miRNA activity, strict classification of
cancer-associated miRNAs into onco- or tumor-suppressor
miRNAs may be an over- simplification. A clear-cut
example is miR-10b: the expression of this miRNA has
been correlated with migration and invasion in esophageal
cancer cell lines and in breast cancer patients, thus
suggesting its tumor-promoting role [31,32]. However,
different results have recently been reported in gastric
cancer, in which the silencing of miRNA-10b by methyla-
tion was associated with an increase in tumor cell
growth through the activation of the oncogene MAPRE
(microtubulus-associated protein RP/EB family, member 1)
[33]. Matching this report, but in contrast with others
[34], in our dataset miR-10b was down-regulated not only
in the T vs N comparison but also in that of M vs T. miR-
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in the EMT transition, and is involved in cell cycle
regulation as well as in cancer recognition by the immune
system [35-37]. It has several predicted targets according
to the reconstructed networks, including two genes en-
coding proteins involved in ribosomal RNA biogenesis:
UTP14 encodes the U3 small ribonucleoprotein homolog.
DKC1 encodes Dyskerin, an essential nucleolar protein
involved in cell proliferation, where it is required for
the pseudo-uridylation of ribosomal RNA molecules,
and for stabilization of the telomerase RNA component.
Dyskerin overexpression has been recognized as a nega-
tive prognostic factor in advanced stage hepatocellular
carcinomas [38].
Although purely exploratory in nature, due to the
relatively low number of subjects analysed, our data
support the prognostic value of miR-10b (Additional file 1:
Figure S6), in line with available evidence regarding the
role played by this microRNA in cancer biology, according
to both preclinical [32,34,39-41] and clinical models
[34,41-43]. miR-10b over-expression has been associated
not only with enhanced aggressiveness of malignant cells
in a variety of experimental models [32,34,39-41,44,45],
but also with worse prognosis in patients with breast
[34,43] and pancreatic carcinoma [41,42]. To our know-
ledge, our results suggest for the first time the potential
involvement of miR-10b in CRC, with special regard to
the modulation of the biological behavior of metastatic
disease, and deserve further investigation.
When T and M samples were compared in unpaired
analyses, only 5 over- and 6 under-expressed miRNAs
were obtained. Two miRNA pairs were characterized by
inverse down- modulation in the tumor toward metastasis
transition: miR-100 and miR-99a according to the unpaired
comparison.
The similarity in miRNA expression in later stages of
tumor progression may reflect the need to maintain the
tumor-specific processes required for tumorigenesis and
cancer progression. However, it should be emphasized
that any malignant tumor is made up of a heterogeneous
cell population and that the differences measured in
gene profiling experiments are thus the result of average
changes occurring within the tumor.
The integrated analysis method has proved to be very
useful in previous studies with relatively limited numbers
of samples, but was expected to be more powerful when
applied to large matched miRNA-gene expression datasets,
as in this study (i.e., with limited dimensionality curse,
imbalance between the number of estimated genes, and
hybridizations to different samples). In fact, after control-
ling for multiple testing and using a stringent significance
criterion (FDR < 0.01), we were able to identify a set of
3,078 trustworthy miRNA-target relations involving 117
(39%) of 309 selected miRNAs. We then defined a putativepost-transcriptional regulatory network in the light of the
information regarding differentially expressed miRNAs
and genes in the T vs N and M vs T comparisons. The T vs
N network includes two components (unconnected sub-
networks) involving respectively 6 up-regulated and 17
down- regulated miRNAs together with their putative
target genes, some of which are significantly differentially
expressed in the same contrast. The biological meaning
of the smaller component (Figure 2A), pertaining to
the 6 miRNAs up-modulated in the T vs N contrast, is
evidenced by the large proportion of significantly modu-
lated genes among the set of predicted target genes repre-
sented in the network. This observation emphasizes the
fact that the pure number of up- or down-regulated
miRNAs may not really be important in predicting the
effect of miRNA regulation on cell behavior, for which gene
expression is a proxy. Some genes are shared predicted
targets of different miRNAs: the PDCD4 gene, a tumor
suppressor gene, appears to be the target of miR-21,
miR-182 and miR-183, all up- regulated in the T vs N
comparison.
The interplay between the sub-networks suggested to be
modulated by miR-21 and miR-182 deserves comment.
miR-21 is an oncomiR whose role in “licensing” and
supporting the neoplastic process from the earliest
step of tumorigenesis is well-known in several types of
solid tumors; its over-expression has in fact been
detected in pre-neoplastic lesions of colon mucosa and in
advanced adenocarcinomas [46]. The connection between
miR-21 and miR-182 is particularly intriguing, in the light
of the role of miR-182 in cytoskeleton reorganization, a
process which favors the epithelial to mesenchymal transi-
tion and fosters cell proliferation and invasion. Among the
predicted miR-182 targets, ENTPD5 was differentially
down-regulated in our analysis. The gene product is a
member of the family of ectonucleoside triphosphate
diphosphohydrolase (E-NTPDases) enzymes which hydro-
lyse extracellular tri- and diphosphonucleosides, are com-
ponents of cellular purinergic signaling, and are involved
in energy metabolism [47]. Mikula et al. recently showed
that both ENTPD5 mRNA and protein levels progressively
decrease during the transition from normal colon mucosa,
through adenoma to adenocarcinoma [21]. This finding is
in line with our results, which also indicate miR-182 as a
possible regulator of ENTPD5 expression.
The post-transcriptional regulatory network with miRNAs
differentially expressed in the comparison of M vs T was
smaller: only 5 DEMs were modulated, each defining a
network component (Additional file 1: Figure S4). The
substantial overlap of miRNAs observed to be differen-
tially expressed in T vs N and M vs T comparisons, the
absence of differentially expressed genes in the MT net-
work, together with the paucity of pathways significantly
modulated in the same comparison (involving supported
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metastasis development, or in alternative a regulatory
influence operating mainly at the translational level. This
result again stresses the strict dependency of malignant
cells on early molecular events acquired during tumori-
genesis. In this respect, we observed that 22 miRNAs
involved in EMT varied during tumor progression: 19
were differentially expressed in primary tumors compared
with normal tissue and one in liver metastasis compared
with primary tumor, and one, miR-10b, was common to
both comparisons, as shown in Additional file 1: Figure S5.
We observed that the expression of many DEMs involved
in EMT was modulated in tumor development (T vs N
comparison) and then remained stable or at similar levels
in metastasis. We identified various KEGG pathways mod-
ulated in the T vs N contrasts by examining the expression
profiles of all genes supported as targets of DEMs. The
implementation of a method based on gene sets allowed
us to identify significantly modulated pathways, rather
than simply enriched in genes representing the target of
specific miRNA groups. For instance, focusing on T vs N
up-regulated DEMs, miR-182 is involved together with
miR-21, miR-18a, miR-1246 and miR-183 in the modula-
tion of cancer-related pathways, and with miR-150 and
miR-183 in the reprogramming of energy metabolism
(purine and selenoaminoacid metabolism), in which various
down-modulated DEGs were found, including ENTPD5
(Figure 2 and Additional file 1: Table S4). At the same
time, miR-182 was grouped in the cell cycle pathway
together with down-regulated miRNAs. In this way, it may
directly regulate CDKN2B (a CDK inhibitor controlling
G1 progression, down-modulated) and collaborate with
down- regulated miRNAs such as miR-145 and miR-195,
in modulating key genes such as CDC25B, MYC and
PRKDC, involved in cell cycle progression checkpoints
and DNA damage response (Figure 3 and Additional
file 1: Table S4).
Furthermore, we reconstructed mixed regulatory
networks and specific circuits involving miRNAs, TFs
and common target genes. Among some of the most
significant interactions in the mixed network associated
with the strongest correlations, we found the oncogenes
MEIS1 and MYC, RBMS3 (encoding an RNA binding pro-
tein of the c-myc family), SVEP1 (involved in cell adhesion),
LPP (of the LIM family of proteins involved in cell adhesion
and motility), CASP7 (a caspase important in the execution
phase of cell apoptosis) and the validated relation miR-145/
FLI1, involving a well-known “cancer gene”.
These circuits show some of the top interactions
involving miRNAs, TFs and common target genes. An
interesting network component includes miR-145, the
TF MEIS1 (a development and neoplasia gene) and the
REV3L gene (the catalytic subunit of DNA polymerase
zeta, involved in DNA repair and genome stability), alldown-regulated in NTM progression. It is known that
inhibition of REV3 expression induces persistent DNA
damage and growth arrest in cancer cells [48].
Connected circuits involve SOX9, an important cancer
gene, a TF which antagonizes β-catenin, inhibits TCF
activity in cancer cells and modulates cell proliferation
[49]. The other component comprises several circuits
involving miR-17, miR-195 and miR-497 together with
NF1 (a hypoxia-activated gene), TFAP4 (another cancer
gene with prognostic importance in gastric carcinoma),
MYC and HNF1A, and common target genes, which can
mainly be classified as cancer genes.
Conclusions
Using a large dataset of matched miRNA and gene
expression profiles in normal mucosa, primary cancer and
metastasis, we describe the interplay of modulated miRNA
groups in the regulation of gene expression, which in turn
affects modulated pathways important for tumor develop-
ment. The suppressor activity of miR-182 on the ENTPD5
gene was identified for the first time and confirmed in an
independent set of samples.
Methods
Patients and collection of tissue samples
For this study, 46 patients with sporadic colorectal
adenocarcinomas, who underwent surgery at the Univer-
sity of Padova (Surgery Unit, Department of Surgery,
Oncology and Gastroenterology) between March 1994
and September 2008, were selected from the institutional
CRC database. Patients with a known history of a heredi-
tary colorectal cancer syndrome were excluded. The
Ethics Committee of the University Hospital of Padova
approved the study. All patients provided written informed
consent. Enrolled patients did not receive any neo-
adjuvant treatment. Normal mucosa samples were taken
at a minimum distance of 10 centimeters from the tumor
site. All samples were immediately snap-frozen in liquid
nitrogen and stored at −80° until use.
RNA extraction
7 μm sections from each tissue sample were prepared
using a Leica CM 1950 cryostat (Leica Microsystems,
Wetzlar, Germany). Hematoxylin and eosin stained sec-
tions of each specimen were prepared and re-evaluated
by one experienced pathologist (G.E.); only samples with
more than 80% of vital tumor tissue were considered for
RNA extraction in toto. Laser microdissection was
performed on a few frozen samples of primary tumours
and metastases with a proportion of neoplastic cells
lower than 80% using LMD-6000 Laser Microdissec-
tion System (Leica Microsystems, Wetzlar, Germany).
Total RNA from samples was isolated using Trizol (Life
Technology Corp, Carlsbad, CA, USA) according to the
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quantified on a NanoDrop 1000 Spectrophotometer
(NanoDrop Technologies, Waltham, MA, USA). RNA
quality was evaluated by RNA 6000 Nano LabChip
(Agilent Technologies, Santa Clara, CA, USA) on an
Agilent 2100 Bioanalyzer. Samples with RNA integrity
number (RIN) < 6 were excluded.
Expression profiling
miRNA microarray hybridization was performed from
total RNA with the Affymetrix GeneChip miRNA Array
2.0 (Affymetrix Santa Clara, CA, USA). Briefly, 100 ng of
total RNA from each sample were labeled with the
FlashTag Biotin RNA Labeling Kit (Genisphere, Hatfield,
PA, USA) and samples were then hybridized according
to the manufacturer’s instructions.
GeneChip Human Exon 1.0 ST (Affymetrix) microarray
hybridization was performed from the same total RNA
extracted for miRNA profiling. Total RNA (100 ng from
each sample) was labeled with the Ambion WT expression
kit (Ambion Inc, Austin, TX, USA), as provided by the
manufacturer. End-labeling, hybridization, washing and
scanning were performed according to the GeneChip
Whole Transcript (WT) Sense Target Labeling Assay user
manual (Affymetrix), and scanned with an Affymetrix
GCS 3000 7G scanner.
For both miRNAs and exon arrays, a first quality control
check was performed with Affymetrix® Expression Console™
software (v.1.0) to determine the success of hybridizations.
miRNA and gene expression measures were reconstructed
from .cel files by using the Robust Multichip Average
(RMA) method. Signals of 41 probes per gene, on average,
were summarized to estimate gene expression with
EntrezGene-based custom CDF (http://brainarray.mbni.
med.umich.edu/Brainarray), obtaining expression profiles
of 22,517 genes.
Detailed quality control of samples was carried out with
R software: Normalized Unscaled Standard Error (NUSE)
and Relative Log Expression (RLE) for global quality of
signals in each array assessment, and MA plots before and
after RMA for identification of biases associated with
specific intensity classes.
miRNAs detected in fewer than 20 samples were
discarded, without filtering out miRNAs undetected only
in one sample class.
miRNA and gene differential expression
A Significance Analysis of Microarrays (SAM) with an
unpaired two-class design was performed to identify
differences in miRNA expression between groups of
normal mucosa (N), primary tumor (T) and liver metasta-
ses (M) samples.
Differentially expressed genes (DEG) between groups
of N, T and M samples were identified with SAM withan unpaired two-class unpaired design. The cut-off for
significance (determined by tuning parameter delta)
corresponded to a false discovery rate (FDR) < 0.01.
Integrated analysis of miRNAs and gene expression profiles
We integrated target predictions with correlation-based
miRNA and gene expression profile, to identify those
regulatory relationships significantly supported by expres-
sion data. This analysis is based on the assumption that, at
least for miRNAs acting on mRNA stability, the expression
profile of a given miRNA is expected to be inversely corre-
lated with those of its true targets. First, miRNA target pre-
dictions were obtained with miRanda-miRSVR, a method
able to identify miRNA-mRNA interactions involving the
seed sequence as well as non-conserved and non-canonical
sites [50].
Using a genome-wide approach, we considered over
four million miRNA-gene relationships predicted with a
“good” score, 25% of which involved evolutionarily
conserved target sites. Pair-wise Pearson correlations
between miRNA and predicted target gene expression
profiles were then calculated and assigned a statistical
significance (p-value). The FDR (q-value) was used to
correct the correlation significance for multiple testing.
Only miRNA-target relationships with significant correla-
tions (FDR < 0.01) were considered to be supported by
expression profiles.
Considering that expression values ranged from 0 to
15 in log2 scale and that 70% of miRNAs were weakly
expressed, we then focused only on miRNAs with signal
over 5, arbitrarily set to the average value of miRNA
expression.
Enrichment of KEGG pathways
To identify significantly perturbed KEGG pathways for
each considered comparison, we applied the statistical
procedure GAGE [51], which takes into account gene
expression variations in both directions, to genes turning
out to be supported targets of DEMs (p-value < 0.05). In
particular, two strategies were implemented to identify
pathways enriched in genes targets of DEMs, the expres-
sion of which changes in the considered comparisons,
and pathways enriched in DEGs targets of DEMs.
Survival analysis
We investigated the association between the expression
levels of 26 DEMs (present in reconstructed post-
transcriptional regulatory networks) in biopsies obtained
from distinct primary [n = 26] or metastatic [n = 20]
colorectal cancers and patients’ disease- specific survival
(interval between diagnosis of primary or metastatic
disease and death by disease or last follow-up).
Given the relatively low sample size, only univariate
survival analysis was performed, and the Cox proportional
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functional form of the covariates being assumed. The
risk associated with a unit increase in miRNA levels was
expressed as hazard ratio (HR) and its 95% confidence
interval (CI). With Bonferroni’s p-value adjustment for
multiple comparisons, the alpha level of significance
was set at 0.002. In order to illustrate prognosis associated
with different levels of the relevant miRNAs, Kaplan-Meier
survival curves were generated after dichotomizing (high
vs low categories) originally continuous covariates based
on the median values of miRNA expression levels. All ana-
lyses were performed with Stata/SE software (version 11.0,
StataCorp LP, College Station, TX, USA).
Quantitative RT-PCR
To confirm array data for miR-150, miR-146a, miR-10b,
miR-122 and miR-210 and to validate miR-145/c-Myc and
miR-182/ENTPD5 relationships, we conducted qRT- PCR
experiments, as previously described [52]. Briefly, experi-
ments were performed three times in triplicate with a
LightCycler 480 II (Roche Diagnostics, Basel, Switzerland)
and were analysed by the ΔΔCt method. Quantification
of the five selected miRNAs, miR-145 and c-Myc was
normalized against internal housekeeping controls, selected
for their minimum variability (measured as expression
profile Shannon entropy). RNU44 and GAPDH were used
as internal controls, respectively for miR-182 and ENTPD5
gene expression quantification.
Luciferase reporter assay
HEK293T cells were plated in 24-well plates at 8×104
cells/well and cotransfected using Lipofectamine 2000
(Invitrogen), with 500 ng pMir target vector customized
for ENTPD5 3′UTR (OriGene Technologies, Rockville,
MD, USA) and 250 ng pRL-TK (Promega, Milan, Italy)
following the manufacturers’ instructions. For miR-182
analysis, cells were cotransfected with non-target RNA
(Tema ricerca, Bologna, Italy) as negative control or
miCENTURY OX miNatural for hsa miR-182 (Tema
ricerca), in triplicate. For the above analyses, cell lysates
were analysed 30 hours after transfection by the Dual-Glo
Luciferase Assay System (Promega) and experiments were
independently repeated three times.
Reconstruction of mixed miRNA-TF networks and circuits
Matched miRNA and gene expression data were analysed
with MAGIA2 to construct mixed miRNA-TF networks
and circuits. MAGIA2 was run on the expression data
for the top 75% of genes with greatest differences in ex-
pression and of 70 DEMs in TN and/or MT comparisons.
The TargetScan (default settings) method was selected
for miRNA target prediction. For TFs, MAGIA2 utilizes
experimentally validated TF– miRNA interactions from
mirGen2.0 and TransmiR and on TF–gene interactionsfrom the ‘TFBS conserved’ track of the UCSC human
genome annotation. Pearson’s correlation was used as a
profile association measure.
Additional file
Additional file 1: The following additional data is available with the
online version of this paper. Additional data includes Supplementary
Methods and Results, Additional file 1: Figures S1- S7 and Additional file 1:
Tables S1-S4.
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